Conversely, Sharifi et al. reported the favorable outcome in high BCL2/BAX ratio in Paclitaxel resistant breast cancer cell-line (25), and Jaafar et al. reported no significance between BCL2, BAX expression and breast tumor cells and angiogenesis of the tumor (26). This evidence concerns the gene BAX and neoplasm.